Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HUA MEDICINE
華領醫藥
(Incorporated in the Cayman Islands with limited liability)
(stock code: 2552)

VOLUNTARY ANNOUNCEMENT
FIRST COMBINATION STUDY OF DORZAGLIATIN WITH A DPP-4 INHIBITOR IN THE UNITED STATES

This nnouncement is m de by Hu Medicine (the "**Company**", together with its subsidi ries, the "**Group**") on volunt ry b sis to inform the sh reholders of the Comp ny nd potenti l investors bout the l test business upd tes of the Group.

The Comp ny is ple sed to nnounce dosing of the first p tient in clinic l tri l of HMS5552 (Dorz gli tin) in p tients with insufficiently 382..olled blood glucose levels with metformin, DPP-4 inhibitor, or SGLT-2 inhibitor, lone or in combin tion ther py. The tri l is ph rm cokinetic (PK) nd ph rm codyn mic (PD) study of dorz gli tin in combin tion with sit gliptin to investig te the PK/PD of e ch drug lone or in combin tion. This tri l is conducted in the United St tes.

In this open l bel, sequenti l, multiple-dose study, p tients will receive DPP-4 inhibitor (sit gliptin) lone, DPP-4 inhibitor in combin tion with dorz gli tin, nd dorz gli tin lone, sequenti lly. The prim ry endpoints re ph rm cokinetic nd ph rm codyn mic inter ction between dorz gli tin nd sit gliptin, nd s fety nd toler bility of dorz gli tin with simult neous dministr tion of sit gliptin.

There re 435 million individu ls with T2D glob lly, with di gnosis r te of 54.2%. Di betes imposes l rge economic burden on the glob l he lthc re system, costing pproxim tely US$850 billion glob lly in 2017. Currently pproved di betes ther pies c nnot effectively 382..ol the progression of di betics into more dv nced st ges of the dise ses, which then le ds to the m ny complic tions ssoci ted with severe di betes, such s loss of vision, peripher l neurop thy, imp ired kidney function, c rdiov scul r dise se, nd stroke.